CervoMed Inc. CRVO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
CervoMed Inc. (CRVO) is a healthcare company listed in the US with a market value of about $26M. In the twelve months to September 30, 2026 it had revenue of $8726 and net income of -$29M, a net margin of -326822.5%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -78%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
About CervoMed
CervoMed is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1645% over three years (dilution for shareholders). It spends 545% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8726 | $4M | $10M | $7M | $0 | — | — | — | — | — | — |
| Net income | -$29M | -$27M | -$16M | -$2M | -$6M | -$24M | -$14M | -$12M | -$18M | -$1M | -$18M |
| Free cash flow | — | — | — | — | — | — | — | — | — | -$13M | -$11M |
| EPS (diluted) | $-2.77 | $-2.98 | $-2.02 | $-0.82 | $2038891.00 | $1946859.00 | $53831973.00 | $6706509.00 | $3242301.00 | $-29.11 | $-26.47 |
| Net margin | -326822.5% | -673.1% | -167.3% | -30.4% | — | — | — | — | — | — | — |
| ROIC | — | -122.7% | -36.7% | -83.7% | — | -69.4% | -57.2% | -44.8% | -118.6% | -29.4% | -155.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is CervoMed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CervoMed pay a dividend?
Not currently.
Is CervoMed a good stock to buy?
We do not give buy or sell advice. CervoMed scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.